Conventional Glioblastoma Multiforme
Conventional glioblastoma multiformes most frequently harbor alterations in CDKN2A, CDKN2B, PTEN, EGFR, and TP53 .
CDKN2A Loss, CDKN2B Loss, TP53 Mutation, PTEN Mutation, and EGFR Amplification are the most common alterations in conventional glioblastoma multiforme .
There are 8 clinical trials for conventional glioblastoma multiforme, of which 8 are open and 0 are completed or closed. Of the trials that contain conventional glioblastoma multiforme as an inclusion criterion, 3 are phase 1 (3 open), 3 are phase 1/phase 2 (3 open), and 2 are phase 2 (2 open).
Temozolomide, brcx014, and g207 are the most common interventions in conventional glioblastoma multiforme clinical trials.
2. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 6. This dataset does not represent the totality of the genetic landscape; see paper for more information.